EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Saccharomyces boulardii as a Probiotic Supplement in Helicobacter pylori Eradication Therapy: A Meta-analysis

Johannes Raphael Westphal, Nadine Koch, Ramiro Vilchez-Vargas, Riccardo Vasapolli, Peter Malfertheiner, Christian Schulz

Journal of Gastrointestinal and Liver Diseases · 17.07.2026 · 35 (3) · 435-444

DOI: 10.15403/jgld-6797 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Journal of Gastrointestinal and Liver Diseases, online erschienen am 17.07.2026. Verfasst von Johannes Raphael Westphal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine II, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, München; German Center for Infection Researc…. Hauptthemen laut MEDLINE: Probiotics, Helicobacter Infections, Saccharomyces boulardii, Helicobacter pylori. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims: Helicobacter pylori (H. pylori) is an obligate pathogen affecting approximately 50% of the world population. With rising antibiotic resistance rates in H. pylori and increasing dropout rates from eradication therapies due to adverse effects, H. pylori treatment is increasingly challenged. Saccharomyces boulardii (S. boulardii), a probiotic yeast, was shown to reduce infection- and therapy-associated adverse events and increase H. pylori eradication rates. Our meta-analysis summarizes the beneficial effects of S. boulardii supplementation on H. pylori eradication and therapy-associated side effects.

Methods

We conducted a systematic literature review and meta-analysis on PubMed, Cochrane Library, and Google Scholar from inception (1993) to October 24, 2024. Research and analysis were performed in accordance with the ‘Preferred Reporting Items of Systematic Reviews and Meta-Analyses’ (PRISMA) guidelines.

Results

The supplementation of S. boulardii to H. pylori therapy caused a significant increase in overall eradication rates and a significant decrease in overall diarrhea, nausea, and epigastric pain rates. Subgroup analysis showed that S. boulardii supplementation also decreased taste disturbance rates in patients receiving triple therapy. Symptoms, such as meteorism, vomiting, and urticaria/rash, were not significantly reduced through the supplementation of S. boulardii.

Conclusions

S. boulardii was shown to be an effective add-on to H. pylori eradication therapy. Significant improvements in eradication and frequency of the most common adverse events were observed. However, more studies are needed to validate those findings for patients receiving bismuth-based quadruple therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProbioticsHelicobacter InfectionsSaccharomyces boulardiiHelicobacter pyloriAnti-Bacterial AgentsHumansDrug Therapy, CombinationTreatment OutcomeProton Pump Inhibitors

Substanzen

Anti-Bacterial AgentsProton Pump Inhibitors

Autor:innen und Institutionen

  • Department of Medicine II, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, München; German Center for Infection Research (DZIF), Partner Site Munich, München, Germany. johannes.westphal@cam…
  • Department of Medicine II, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, München; German Center for Infection Research (DZIF), Partner Site Munich, München, Germany. nadine.koch@med.uni-m…
  • Department of Medicine II, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, München, Germany. ramiro@rv-v.com.
  • Department of Medicine II, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, München; German Center for Infection Research (DZIF), Partner Site Munich, München, Germany. riccardo.vasapolli@me…
  • Department of Medicine II, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, München; Medical Department Klinik of Gastroenterology, Hepatology and Infectiology, Otto-von-Guericke Universität…
  • Department of Medicine II, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, München; German Center for Infection Research (DZIF), Partner Site Munich, München, Germany. chr.schulz@med.uni-mu…

Zitieren

APA

Westphal, J. R., Koch, N., Vilchez-Vargas, R., Vasapolli, R., Malfertheiner, P., & Schulz, C. (2026). Saccharomyces boulardii as a Probiotic Supplement in Helicobacter pylori Eradication Therapy: A Meta-analysis. Journal of Gastrointestinal and Liver Diseases, 35(3), 435-444. https://doi.org/10.15403/jgld-6797

Vancouver

Westphal JR, Koch N, Vilchez-Vargas R, Vasapolli R, Malfertheiner P, Schulz C. Saccharomyces boulardii as a Probiotic Supplement in Helicobacter pylori Eradication Therapy: A Meta-analysis. Journal of Gastrointestinal and Liver Diseases. 2026;35(3):435-444. doi:10.15403/jgld-6797

BibTeX
@article{Westphal2026,
  author = {Westphal, Johannes Raphael and Koch, Nadine and Vilchez-Vargas, Ramiro and Vasapolli, Riccardo and Malfertheiner, Peter and Schulz, Christian},
  title = {Saccharomyces boulardii as a Probiotic Supplement in Helicobacter pylori Eradication Therapy: A Meta-analysis},
  journal = {Journal of Gastrointestinal and Liver Diseases},
  year = {2026},
  volume = {35},
  number = {3},
  pages = {435--444},
  doi = {10.15403/jgld-6797}
}
Kostenlos starten →